Medtronic to Unveil Additional Clinical Data on HVAD® System at ISHLT 2018
April 09 2018 - 4:00PM
Data on Implant
Approach, Blood Pressure Management, Length of Stay, and Quality of
Life
to be Featured During Congress.
DUBLIN - April 9, 2018 -
Medtronic plc (NYSE: MDT) today announced a preview of notable
clinical data on the HeartWare HVAD® System that will be presented
at The International Society of Heart and Lung Transplantation
(ISHLT) Scientific Sessions, from April 11-14, 2018, in Nice,
France. The HVAD System is a mechanical heart pump (also called a
left ventricular assist device, or LVAD) that helps increase the
amount of blood that flows through the body in patients with
advanced heart failure.
"ISHLT is the pre-eminent gathering of clinicians
involved in caring for patients with advanced heart or lung
disease, including heart transplants and mechanical circulatory
support. Medtronic is pleased to collaborate with physicians to
share the latest clinical evidence that advances MCS therapy," said
Mike Hess, general manager of the Mechanical Circulatory Support
business, part of the Cardiac and Vascular Group at Medtronic.
The congress agenda highlights several
presentations featuring the HVAD System (all times CEST):
Wednesday, April 11
-
8:30-10 a.m., Apollon: Blood Pressure Management
Ameliorates the Severity of Neurological Events, JJ Teuteberg,
Stanford University
Thursday, April 12
-
6:15-7:15 p.m., Uranie/Calliope: An Analysis of
Preceding Signals and Treatment Strategies of VAD Thrombus in the
ENDURANCE and ENDURANCE SUPPLEMENTAL Trials, FD Pagani, University
of Michigan
Friday, April 13
-
6:15-7:15 p.m., Hermes: Infections and
Subsequent Events in the ENDURANCE and ENDURANCE Supplemental
Trials, RL Kormos, University of Pittsburgh
Saturday, April 14
-
1:15 p.m., Athena: The Effects of Concomitant
Procedures at the Time of LVAD Implant for Patients in the
ENDURANCE and ENDURANCE Supplemental Trials, NA Mokadam, University
of Washington
Featured posters include:
-
Adverse Events and their Effect on Quality of
Life and Functional Capacity in the ENDURANCE and ENDURANCE
Supplemental Trials
-
Does Increasing Experience in Implementing the
Blood Pressure Management Protocol in the ENDURANCE Supplemental
Trial Result in Better Outcomes?
-
Change in Heart Rate from Pre-Implant to
Discharge in Destination Therapy is Associated with Mortality and
Admissions in LVAD Patients - A Substudy of the ENDURANCE
trial
Details such as times, presenters and locations
are subject to change.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 84,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Tracy McNulty
Public Relations
+1-763-526-2492
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024